(ISSN 2638-1311)
OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2024): Submission to First Decision: 6.3 weeks; Submission to Acceptance: 11.4 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Research in Neurodegenerative Diseases II
Submission Deadline: September 15, 2022 (Open) Submit Now
Guest Editor
Janusz Wieslaw Blaszczyk,
PhD, DSc, Professor
Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
Website1 | Website2 | Website3 | E-Mail
Research Interests：Neuroscience； Neurophysiology； Brain aging； Neurodegeneration
About This Topic
Neurodegenerative diseases consist of a group of pathologies related to the progressive dysfunction of neuronal networks in the human brain. Neurodegeneration can be found in the brain at many different levels of neuronal circuitry, ranging from molecular to systemic. Neurodegenerative diseases are incurable and debilitating conditions being the result of massive degeneration and death of brain cells. Depending on the most affected area patients exhibit mental and motor dysfunctions. The incidence of main neurodegenerative pathologies, such as Alzheimer’s and Parkinson's disease, increases with age. To understand and counteract such pathologies, we need to understand their immediate causes at the cellular level. It seems that many neurodegenerative diseases are caused by genetic mutations. More recently, however, appeared the concept of a vicious cycle in neuronal energy metabolism that may readily explain the involution of the neuronal networks. The decreasing activity of the strategic brain structures, in turn, results in their metabolic deprivation that disturbed cellular homeostasis and finally initiate preprogrammed death of neuronal cells. With the increasing understanding of the pathophysiological basis of these disorders, appears now a realistic prospect for developing therapies that may slow, or control the process of neurodegeneration. Importantly therapeutic advances against one neurodegenerative disease might ameliorate other diseases as well.
Keywords
Neurodegenerative disorders; Brain homeostasis; Aging brain; Genetic background; Energy metabolism; Brain involution
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Emerging Roles of Signal Transduction Pathways in Neurodegenerative Diseases. Hunting New Possible Therapeutic Molecular TargetsAbstract Illnesses following the degeneration of the nervous system can occur due to aging or genetic mutations and represent a clinical concern. In neurodegenerative diseases, loss of neuronal structure and functions mainly causes cognitive impairment, representing an increasing social burden. In neurodegenerative diseases, the progressive loss of [...] |
TOP
